|1.||Egorin, Merrill J: 5 articles (08/2008 - 08/2004)|
|2.||Zamboni, William C: 5 articles (08/2008 - 08/2004)|
|3.||Strychor, Sandra: 5 articles (08/2008 - 08/2004)|
|4.||Pantazis, P: 5 articles (10/2001 - 09/2000)|
|5.||Ramanathan, Ramesh K: 4 articles (07/2006 - 08/2004)|
|6.||Knight, V: 4 articles (03/2002 - 01/2000)|
|7.||Wyche, J H: 4 articles (10/2001 - 09/2000)|
|8.||Jin, Ruzhi: 3 articles (07/2005 - 08/2004)|
|9.||Jung, Laura L: 3 articles (07/2005 - 08/2004)|
|10.||Schellens, Jan H M: 3 articles (09/2004 - 08/2002)|
|1.||Pancreatic Neoplasms (Pancreatic Cancer)
07/01/2005 - "9-Nitrocamptothecin has completed phase III studies in patients with newly diagnosed and refractory pancreatic cancer; however, the optimal 9-nitrocamptothecin treatment regimen is unclear. "
03/01/2005 - "Phase II trial of oral rubitecan in previously treated pancreatic cancer patients."
05/01/1999 - "A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer."
03/01/2005 - "Oral rubitecan produced responses and was well tolerated by heavily pretreated patients with refractory pancreatic cancer. "
01/01/2004 - "In June 2003, the EMEA granted SuperGen orphan drug status for rubitecan for the treatment of pancreatic cancer. "
04/01/2011 - "The purpose of this study is to evaluate the pharmacokinetics and safety of 9-nitrocamptothecin in patients with advanced solid tumors. "
04/01/2011 - "A phase I pharmacokinetics study of 9-nitrocamptothecin in patients with advanced solid tumors."
01/01/2006 - "Results of clinical trials in the next few years should determine whether rubitecan can find a role in cancer therapy."
12/01/2004 - "Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors."
08/01/2004 - "Phase I and pharmacologic study of intermittently administered 9-nitrocamptothecin in patients with advanced solid tumors."
|3.||Neoplasm Metastasis (Metastasis)
03/01/2002 - "Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin."
07/01/2000 - "To determine whether this approach has utility against pulmonary metastases, the efficacy of aerosol therapy with liposome-encapsulated 9-nitrocamptothecin (L-9NC) was determined using two different experimental lung metastasis models. "
07/01/2000 - "9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice."
03/01/2002 - "We previously demonstrated that aerosol delivery of dilauroylphosphatidylcholine liposome formulation of 9-nitrocamptothecin (9NC-DLPC) inhibits B16-F10 melanoma lung metastases. "
01/01/2000 - "9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice."
01/01/2004 - "Results from an ongoing phase II study in cancer patients have shown that rubitecan was effective against chordomas, a rare type of bone cancer. "
07/01/2013 - "We identified a group of drugs including bortezomib, 17-AAG, digitoxin, staurosporine, digoxin, rubitecan, and trimetrexate that inhibited chordoma cell growth, with potencies from 10 to 370 nM in U-CH1 cells, but less potently in U-CH2 cells. "
|5.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
|4.||exatecan (DX 8951f)
|5.||Type I DNA Topoisomerases (Topoisomerase I)
|9.||Topoisomerase I Inhibitors
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)